ConductScience.org, home
Efficacy and Safety of ALXN1840 Administered for 48 Weeks Versus Standard of Care in Participants With Wilson Disease
API referenceFor AI assistants

Trial · NCT03403205

Participant flow54

How many started, completed or left each group, period by period.

1 to 20 of 54

Download this page as JSON
PeriodMilestoneGroupParticipantsUnits counted
Primary Evaluation Period (48 Weeks)STARTEDCohort 1: ALXN1840105
Primary Evaluation Period (48 Weeks)STARTEDCohort 1: SoC Therapy56
Primary Evaluation Period (48 Weeks)STARTEDCohort 2: ALXN184037
Primary Evaluation Period (48 Weeks)STARTEDCohort 2: SoC Therapy16
Primary Evaluation Period (48 Weeks)STARTEDCohort 1: WTX101-201- ALXN18400
Primary Evaluation Period (48 Weeks)STARTEDCohort 2: WTX101-201- ALXN18400
Primary Evaluation Period (48 Weeks)Received at Least 1 Dose of Study DrugCohort 1: ALXN1840104
Primary Evaluation Period (48 Weeks)Received at Least 1 Dose of Study DrugCohort 1: SoC Therapy56
Primary Evaluation Period (48 Weeks)Received at Least 1 Dose of Study DrugCohort 2: ALXN184033
Primary Evaluation Period (48 Weeks)Received at Least 1 Dose of Study DrugCohort 2: SoC Therapy14
Primary Evaluation Period (48 Weeks)Received at Least 1 Dose of Study DrugCohort 1: WTX101-201- ALXN18400
Primary Evaluation Period (48 Weeks)Received at Least 1 Dose of Study DrugCohort 2: WTX101-201- ALXN18400
Primary Evaluation Period (48 Weeks)Completed PEP, Enter ExtensionCohort 1: ALXN184089
Primary Evaluation Period (48 Weeks)Completed PEP, Enter ExtensionCohort 1: SoC Therapy49
Primary Evaluation Period (48 Weeks)Completed PEP, Enter ExtensionCohort 2: ALXN184028
Primary Evaluation Period (48 Weeks)Completed PEP, Enter ExtensionCohort 2: SoC Therapy12
Primary Evaluation Period (48 Weeks)Completed PEP, Enter ExtensionCohort 1: WTX101-201- ALXN18400
Primary Evaluation Period (48 Weeks)Completed PEP, Enter ExtensionCohort 2: WTX101-201- ALXN18400
Primary Evaluation Period (48 Weeks)Completed PEP, Not Into ExtensionCohort 1: ALXN18404
Primary Evaluation Period (48 Weeks)Completed PEP, Not Into ExtensionCohort 1: SoC Therapy3

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Next page

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT03403205/flow

API referenceFor AI assistants